To familiarize obstetrician–gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS).
Using OVID, 94 English-language articles published after 1966 indexed with the key words “metformin” and “polycystic ovary syndrome” were identified.
Studies were excluded if they did not have a control group, did not use the National Institutes of Health definition of PCOS, did not have a clinical outcome as an end point, and were not in the English language. Reviews were also excluded, leaving 21 articles for inclusion.
Three clinical trials reported that for the treatment of anovulatory infertility caused by PCOS, metformin plus clomiphene is more effective than clomiphene alone in inducing ovulation. For the treatment of irregular menses caused by PCOS in women not attempting conception, metformin therapy may restore ovulatory menses in the majority of women. However, most women will require 4–6 months of metformin therapy before they achieve ovulatory menses. In obese women, metformin plus a low-calorie diet may be associated with more weight loss than a low-calorie diet alone.
Polycystic ovary syndrome is a common gynecologic endocrine disorder. Obstetrician–gynecologists should be familiar with the indications and contraindications for the use of metformin in their practice.
Metformin is effective in combination with clomiphene for the induction of ovulation; gynecologists should be familiar with the indications and contraindications for use of metformin.
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Address reprint requests to: Robert L. Barbieri, MD, Brigham and Women's Hospital, Harvard Medical School, Department of Obstetrics and Gynecology, 75 Francis Street, Boston, MA 02115; E-mail: firstname.lastname@example.org.
Supported, in part, by National Institutes of Health grant HD-U54-29164.
Received July 8, 2002. Received in revised form August 30, 2002. Accepted September 12, 2002.